Global Head and Neck Cancer Therapeutics Market
stood at USD2024.33 million in 2021 and is expected to grow at an impressive
rate of 7.22% during the forecast period. This can be ascribed to the growing
popularity of precision medicine and the need for new therapies for the
treatment of different types of head and neck cancers. Furthermore, growing
consumption of tobacco and alcohol is further contributing to the increasing
incidences of head and neck cancers. According to World Health Organization,
Tobacco kills nearly half of its users, accounting for around 8 million deaths
every year. Out of which, 7 million deaths are caused due to direct tobacco
use, while the remaining is caused due to the exposure of nonsmokers to passive
smoking.
Increasing Number of Clinical Trials
The increasing research & development
activities related to the development of different types of therapies related
to head and neck cancer has significantly augmented the number of clinical
trials related to the same. There are around 2957 clinical trials launched on
head and neck cancer till date. In 2021, around 52 clinical trials were
launched globally related to head and neck cancer. This count is expected to
increase in the coming years, thereby supporting the market growth in the
coming years.
Growing Adoption of New Treatments
Development of immunotherapies, CAR-T cell
therapies, among others for the treatment of different types of cancer is
expected to drive the growth of head and neck cancer therapeutics market.
Several clinical trials related to immunotherapies and targeted therapies are
going on. In the forecast period, several advanced therapies can be expected to
treat head and neck cancer.
Increasing Number of Players
Many healthcare players are either developing drugs
or therapies for the treatment of head and neck cancer or collaborating with
other companies who have developed the therapy or drug earlier. Some healthcare
majors are simply acquiring the smaller ones and expanding their portfolio of
head and neck cancer therapeutic solutions. This, in turn, is leading to a lot
of investment in the head and neck cancer therapeutics industry. For instance,
in January 2021, AbbVie, Inc. developed SkinMedica Neck Correct Cream, which
focuses on the biology of the skin on the neck and decollete area.

Click here to download the sample
Market Segmentation
The global head and neck cancer therapeutics market
is segmented by type, diagnostic methods, treatment type, disease indication,
route of administration, therapeutic class, end user, region, and company.
Based on type, the global head and neck cancer therapeutics market can be split
into diagnostic methods and treatment types. Diagnostics methods can be further
categorized into Biopsy, Imaging, Endoscopy and Others. While treatment type
can be further fragmented into Surgery, Radiation Therapy, Chemotherapy,
Immunotherapy and Targeted Therapy. Disease indication segment can be
fragmented into Lip and Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal
Cancer, Nasopharyngeal Cancer, Salivary Gland Cancer and Hypopharyngeal Cancer.
The Route of Administration can be split into Injectable and Oral. Therapeutic
Class can be categorized as PD Inhibitors (PD-1 and PD-L1), EGFR Inhibitors and
Microtubule Inhibitors. In terms of end user, the global head and neck cancer
therapeutics market can be categorized as Hospitals, Specialty Clinics,
Ambulatory Surgical Centers, And Others. Regionally, the Head and Neck Cancer
Therapeutics Market can be categorized into North America, Asia Pacific,
Europe, South America, and Middle East & Africa. North America dominates
the overall Head and Neck Cancer Therapeutics Market with United States having
the biggest market. The United States Head and Neck Cancer Therapeutics Market
stood at USD562.21 million in 2021.
Major companies in the market are Eli Lilly and
Company, Bristol Myers Squibb Company, Sanofi S.A., Merck & Co., Inc.,
Pfizer Inc, AbbVie Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Fresenius Medical
Care AG & Co. KGaA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical
Industries Limited, AstraZeneca Plc., Astellas Pharma Inc., AB Science SA,
Boston Biomedical, Inc., among others. Major players operating in the market
are following strategies such as mergers and acquisitions, new therapy or drug
launches, and others to stay competitive and have an edge over other players in
the market.
Attribute
|
Details
|
Market
Size Value in 2021
|
USD2024.33
million
|
Revenue
Forecast in 2027
|
USD3126.26 million
|
United
States Market Size Value in 2021
|
USD562.21
million
|
Growth
Rate
|
7.22%
|
Base
Year
|
2021
|
Historical
Years
|
2017 – 2020
|
Estimated
Year
|
2022
|
Forecast
Period
|
2023 – 2027
|
Quantitative
Units
|
Revenue
in USD Million and CAGR for 2017-2021 and 2022-2027
|
Report
Coverage
|
Revenue forecast, company share,
competitive landscape, growth factors, and trends
|
Segments
Covered
|
·
Type
o
Diagnostic Methods
o
Treatment Type
§ Disease Indication
§ Route of Administration
§ Therapeutic Class
·
End User
|
Regional
Scope
|
North America; Asia Pacific;
Europe, South America; Middle East & Africa
|
Country
Scope
|
United
States; Canada; Mexico; Germany; France; United Kingdom; Italy; Spain; China;
India; Japan; Australia; South Korea; Singapore; Brazil; Argentina; Colombia;
South Africa; Saudi Arabia; UAE
|
Key
Companies Profiled
|
Eli
Lilly and Company, Bristol Myers Squibb Company, Sanofi S.A., Merck &
Co., Inc., Pfizer Inc, AbbVie Inc., Bayer AG, F. Hoffmann-La Roche Ltd.,
Fresenius Medical Care AG & Co. KGaA, Sun Pharmaceutical Industries Ltd.,
Teva Pharmaceutical Industries Limited, AstraZeneca Plc., Astellas Pharma
Inc., AB Science SA, Boston Biomedical, Inc.
|
Customization
Scope
|
10%
free report customization with purchase. Addition or alteration to country,
regional & segment scope.
|
Pricing
and Purchase Options
|
Avail customized purchase
options to meet your exact research needs. Explore purchase options
|
Delivery
Format
|
PDF and Excel through Email (We
can also provide the editable version of the report in PPT/Word format on
special request)
|
Report
Scope:
In this
report, global Head and Neck Cancer Therapeutics market has been segmented into
following categories, in addition to the industry trends which have also been
detailed below:
- Head and Neck Cancer Therapeutics Market, By Type:
- Diagnostic Methods
- Biopsy
- Imaging
- Endoscopy
- Others
- Treatment Type
- Surgery
- Radiation Therapy
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Head and Neck Cancer Therapeutics Market, By Disease
Indication:
- Lip and Oral Cavity Cancer
- Laryngeal Cancer
- Oropharyngeal Cancer
- Salivary Gland Cancer
- Nasopharyngeal Cancer
- Hypopharyngeal Cancer
- Head and Neck Cancer Therapeutics Market, By Route of
Administration:
- Head and Neck Cancer Therapeutics
Market, By
Therapeutic Class:
- PD Inhibitors
- EGFR Inhibitors
- Microtubule Inhibitors
- Head and Neck Cancer Therapeutics
Market, By
End User:
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Others
- Head and Neck Cancer Therapeutics Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- Singapore
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive
Landscape
Company Profiles: Detailed
analysis of the major companies present in global Head and Neck Cancer
Therapeutics market.
Available
Customizations:
With the given market data,
TechSci Research offers customizations according to a company’s specific needs.
The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of
additional market players (up to five).
In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com